These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26666158)

  • 1. [SGLT2 inhibitor].
    Kubota N; Kadowaki T
    Nihon Rinsho; 2015 Dec; 73(12):2091-5. PubMed ID: 26666158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?
    Bertinat R; Nualart F; Yáñez AJ
    J Cell Physiol; 2016 Aug; 231(8):1635-7. PubMed ID: 26661279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
    Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA; Wright EM; Vallon V
    Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
    Bakris GL; Fonseca VA; Sharma K; Wright EM
    Kidney Int; 2009 Jun; 75(12):1272-1277. PubMed ID: 19357717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.
    Nair S; Wilding JP
    J Clin Endocrinol Metab; 2010 Jan; 95(1):34-42. PubMed ID: 19892839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renal aspects of sodium glucose cotransporter 2 inhibitors].
    Beaud F; Pruijm M; Humbert A; Burnier M; Zanchi A
    Rev Med Suisse; 2015 Feb; 11(463):488-92. PubMed ID: 25898456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.
    Santer R; Calado J
    Clin J Am Soc Nephrol; 2010 Jan; 5(1):133-41. PubMed ID: 19965550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?
    Tönjes A; Kovacs P
    Pharmacogenomics; 2013 May; 14(7):825-33. PubMed ID: 23651029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
    DeFronzo RA; Norton L; Abdul-Ghani M
    Nat Rev Nephrol; 2017 Jan; 13(1):11-26. PubMed ID: 27941935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.
    Xu B; Li S; Kang B; Fan S; Chen C; Li W; Chen J; He Z; Tang F; Zhou J
    Mol Biol Rep; 2023 Nov; 50(11):9637-9647. PubMed ID: 37819499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks Associated with SGLT2 Inhibitors: An Overview.
    Singh M; Kumar A
    Curr Drug Saf; 2018; 13(2):84-91. PubMed ID: 29485006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved glycemic control in mice lacking Sglt1 and Sglt2.
    Powell DR; DaCosta CM; Gay J; Ding ZM; Smith M; Greer J; Doree D; Jeter-Jones S; Mseeh F; Rodriguez LA; Harris A; Buhring L; Platt KA; Vogel P; Brommage R; Shadoan MK; Sands AT; Zambrowicz B
    Am J Physiol Endocrinol Metab; 2013 Jan; 304(2):E117-30. PubMed ID: 23149623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
    Lapuerta P; Zambrowicz B; Strumph P; Sands A
    Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
    Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
    Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
    Girard J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.